Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

NewsGuard 100/100 Score
Apr 15 2010

Pharmasset, Inc. (Nasdaq: VRUS) announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously.  PSI-7977 is Pharmasset's nucleotide analog for the treatment of HCV.  The Company announced the interim results in conjunction with the European Association for the Study of Liver Congress that commenced in Vienna, Austria on April 14, 2010.


Source:

Pharmasset, Inc.

Posted in: Drug Trial News | Disease/Infection News

Tags: , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
COVID-19 vaccines show moderate success in preventing long COVID in kids
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show
Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine
Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management
Nanobots for bladder cancer treatment, promising high efficacy and targeted delivery
The efficacy of the Mediterranean diet on health outcomes in adults with cancer
Scientific review explores adzuki beans' efficacy in diabetes prevention and management

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in Crohn’s disease